Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4402 Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomised study of cessation of somatostatin analogues after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours

Introduction: After progressing on somatostatin analogues (SSA), patients with somatostatin receptor positive gastroenteropancreatic (GEP) NETs often receive PRRT. It is unclear whether current practice of continuing SSA after commencing PRRT is beneficial, especially in non-functioning NETs.

Conference:

Presenting Author:

Authors: Burge M, Wyld D, Pattison D, Loree J, Goodwin R,

Keywords: Somatostatin analogue, peptide receptor radionuclide therapy, gastroenteropancreatic, neuroendocrine, non-functioning, cessation, Australasian Gastro-Intestinal Trials Group (AGITG), Canadian Cancer Trials Group (CCTG),

#3698 PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma

Introduction: Management of metastatic insulinoma (MI) presents dual management challenges of hypoglycaemia (hypo) and progressive oncologic disease. Case reports describe remarkable responses to PRRT but limited follow-up (FU).

Conference:

Presenting Author: Pattison D

Authors: Pattison D, Kong G, Hofman M, Akhurst T, Ravi Kumar A,

Keywords: Insulinoma, PRRT, hypoglycaemia, [177Lu]Lu-DOTATATE,

#2119 Positron Emission Tomography (PET) Predictors of Tumor Response to Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors (NET)

Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate (68Ga-DOTATATE) PET standardised uptake value (SUV) has shown conflicting results in the prediction of tumour response to radionuclide therapy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,

Keywords: 68Ga-DOTATATE PET-CT, SUV parameters, Tumor response, Somatostatin receptor tumor volume,

#2069 Tumor Absorbed Dosimetry and Response of Radionuclide Therapy in Metastatic Neuroendocrine Tumor

Introduction: Increased tumour lesion absorbed dosimetry (TLAD) from peptide receptor radionuclide therapy (PRRT) is associated with neuroendocrine tumours (NET) response. Responses to PRRT might be impacted by NET grade, site of origin and use of concurrent chemotherapy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,

Keywords: 68Ga-DOTATATE PET, Tumor Dosimetry, Response,

#2066 Pretherapeutic Predictors of Tumor Absorbed Dosimetry in Radionuclide Therapy for Metastatic Neuroendocrine Tumors

Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate Positron Emission Tomography (68Ga-DOTATATE PET) standardised uptake value (SUV) has shown conflicting results in the prediction of tumour lesion absorbed dosimetry (TLAD).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burg M,

Keywords: 68Ga-DOTATATE PET-CT, Tumor Dosimetry, SUV predictors,